Finally, given the promising results of ICIs in HER2-positive G/GEJ adenocarcinoma in the KEYNOTE-811 trial, further exploration of immunotherapy in combination with targeted therapies, such as HER2 inhibitors (trastuzumab), could represent a future frontier for treating this specific patient subset. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.